Results 151 to 160 of about 186,086 (209)

Ocular involvement in newly diagnosed pediatric leukemia: A systematic review and meta‐analysis

Pediatric Investigation, EarlyView.
The global prevalence of ocular involvement in pediatric leukemia is estimated to be 20.32%, which is more common than previously recognized. Given the high rate of asymptomatic involvement, screening for all newly diagnosed leukemia patients is recommended.
Kristina Nazzicone, Rachel Kim, Alexa Fine, Aidan Pucchio, Laura Wheaton, Christine Law   +5 more
wiley   +1 more source

Visualization and hotspot analysis of CAR‐T research based on CiteSpace

Precision Medical Sciences, EarlyView.
Articles on CAR‐T cells were collected from the Web of Science Core Collection (WoSCC). Key bibliometric characteristics were analyzed using CiteSpace. Our findings showed that CAR‐T cell therapy is a cutting‐edge field that has drawn a lot of interest, that its depth and excitement for research are growing, and that it may face further challenges and ...
Kejin Li, Yue Teng, Weiyan Tang, Liuliu Zhang, Xiaoxu Zhi, Wenjuan Li, Jianqiu Wu   +6 more
wiley   +1 more source

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 583-595, March 2025.
ABSTRACT Prior pharmacokinetic (PK) analysis revealed that increased alpha‐1‐acid glycoprotein (AAG) levels are associated with decreased imatinib unbound fraction in coronavirus disease 2019 (COVID‐19) patients. This study aimed to investigate the PK of total and unbound concentrations of imatinib and the metabolite N‐desmethyl imatinib in ...
Medhat M. Said, Job R. Schippers, Leila Atmowihardjo, Yingxue Li, Mick S. van der Plas, Harm J. Bogaard, Lieuwe D. J. Bos, Ron A. A. Mathôt, Jurjan Aman, Eleonora L. Swart, Imke H. Bartelink   +10 more
wiley   +1 more source

Precision Medicine in Oncology: Imatinib Dosing in the Obese Cancer Population Using Virtual Clinical Trials

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT This study investigates the impact of obesity on imatinib pharmacokinetics in cancer patients by utilizing physiologically based pharmacokinetic modeling (PBPK) and virtual clinical trial approaches and evaluates the effectiveness of therapeutic drug monitoring (TDM)–guided dose adjustment to recover the imatinib trough concentration (Cmin ...
Khairulanwar Burhanuddin, Afzal Mohammed, Nurul Afiqah Burhanuddin, Raj K. S. Badhan   +3 more
wiley   +1 more source

Push Forward Clinical Management of Hematological Toxicity due to Lenalidomide Overexposure: Model‐Informed Precision Dosing for Chinese Population With Renal Insufficiency

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Dose‐dependent hematological toxicity of lenalidomide has been reported previously, and thus, there is a clinical need for dose individualization to manage toxicities. The objectives of this study were to explore optimal individualized dosing regimens for Chinese B‐cell malignancies patients with varying degrees of renal function, and to push ...
Yi Ma, Zaiwei Song, Hao Bing, Huan He, Libo Zhao, Rongsheng Zhao   +5 more
wiley   +1 more source

Malignancies and immunoglobulin G4‐related disease

Rheumatology &Autoimmunity, EarlyView.
Immunoglobulin G4‐related disease (IgG4‐RD) is associated with increased cancer risk. Malignancies affect both IgG4‐RD involved organs, such as the lung, pancreas, bile duct, and prostate, and noninvolved organs, such as the gastrointestinal duct. B‐cell neoplasms constitute a proportion of the malignancies linked to this disease.
Jingna Li, Wen Zhang
wiley   +1 more source

Nature Inspired Delivery Vehicles for CRISPR‐Based Genome Editing

Small, EarlyView.
The review highlights nature‐inspired nanocarriers for CRISPR delivery, emphasizing viral vectors, extracellular vesicles, liposomes, and lipid nanoparticles. It discusses their roles in improving specificity, minimizing immunogenicity, and overcoming barriers in genome editing. Recent advancements, challenges, and therapeutic applications are explored,
Elizabeth Maria Clarissa, Mamata Karmacharya, Hyunmin Choi, Sumit Kumar, Yoon‐Kyoung Cho   +4 more
wiley   +1 more source

Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape

Small, EarlyView.
This review presents a detailed overview of clinically approved nanoparticle therapeutics, classifying them by type and discussing their unique advantages in drug delivery. It highlights regulatory challenges across global markets and emphasizes the need for adaptive approval pathways.
Nimeet Desai, Dhwani Rana, Mitali Patel, Neha Bajwa, Rajendra Prasad, Lalitkumar K. Vora   +5 more
wiley   +1 more source

Recent progress on nanotechnologies for enhancing blood‐brain barrier permeability

Smart Molecules, EarlyView.
In this review, we summarize innovative strategies for harnessing the power of nanotechnology to enhance blood‐brain barrier permeability, a key challenge for central nervous system (CNS) drug delivery. We overview structural innovation of nanocarriers, improvements in targeting strategies, and nanotechnology‐enhanced brain imaging.
Qibin Liu, Zhuoqian Chen, Anthony Guiseppi‐Elie, Fanling Meng, Liang Luo   +4 more
wiley   +1 more source